Vedolizumab
- Generic Name
- Vedolizumab
- Brand Names
- Entyvio
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 943609-66-3
- Unique Ingredient Identifier
- 9RV78Q2002
- Background
Vedolizumab is a recombinant humanized IgG1 monoclonal antibody directed against the human lymphocyte α4β7 integrin, a key mediator of gastrointestinal inflammation implicated in diseases like ulcerative colitis or Crohn's disease. α4β7 integrin facilitates the interaction between lymphocytes and gut endothelial cells through the α4β7 integrin-MAdCAM1 intera...
- Indication
Vedolizumab is indicated for adult patients with moderately to severely active Ulcerative Colitis or Crohn’s disease.
- Associated Conditions
- Moderately to Severely Active Crohn's Disease, Moderately to Severely Active Ulcerative Colitis
- Associated Therapies
- -
Early Biomarkers in Circulating α 4β7 + T Cells to Predict Response to Vedolizumab in Inflamatory Bowel Disease Patients.
- First Posted Date
- 2016-03-18
- Last Posted Date
- 2019-02-28
- Lead Sponsor
- Parc de Salut Mar
- Target Recruit Count
- 24
- Registration Number
- NCT02712866
- Locations
- 🇪🇸
Hospital del Mar, Barcelona, Spain
Clinical and Molecular Phenotyping in IBD
- First Posted Date
- 2016-02-29
- Last Posted Date
- 2022-07-01
- Lead Sponsor
- University Hospital Schleswig-Holstein
- Target Recruit Count
- 90
- Registration Number
- NCT02694588
- Locations
- 🇩🇪
Medical Department I, University Hospital Schleswig-Holstein, Kiel, Germany
OTIS Vedolizumab Pregnancy Exposure Registry
- Conditions
- Interventions
- First Posted Date
- 2016-02-09
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Takeda
- Target Recruit Count
- 303
- Registration Number
- NCT02678052
Entyvio (Vedolizumab) Long Term Safety Study
- Conditions
- Interventions
- First Posted Date
- 2016-02-04
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Takeda
- Target Recruit Count
- 5302
- Registration Number
- NCT02674308
- Locations
- 🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇺🇸University of South Alabama, Mobile, Alabama, United States
🇺🇸University of Arizona Medical Center, Tucson, Arizona, United States
A Study to Evaluate Efficacy, of Early Versus Late Use of Vedolizumab in Crohn's Disease: the LOVE-CD Study
- First Posted Date
- 2016-01-06
- Last Posted Date
- 2023-06-23
- Lead Sponsor
- Geert D'Haens
- Target Recruit Count
- 260
- Registration Number
- NCT02646683
- Locations
- 🇧🇪
Imeldahospital, Bonheiden, Belgium
🇧🇪ULB Erasme, Brussels, Belgium
🇳🇱Academisch Medisch Centrum, Amsterdam, Netherlands
Vedolizumab IV 300 mg in the Treatment of Fistulizing Crohn's Disease
- First Posted Date
- 2015-12-15
- Last Posted Date
- 2019-11-19
- Lead Sponsor
- Takeda
- Target Recruit Count
- 34
- Registration Number
- NCT02630966
- Locations
- 🇫🇷
Hopital de Brabois, Vandoeuvre les Nancy, France
🇫🇷Hopital l'Archet II, Nice Cedex 3, France
🇳🇱Academic Medical Center, Amsterdam, Netherlands
Postmarketing Vedolizumab Milk-Only Lactation Study in Lactating Women With Active Ulcerative Colitis or Crohn's Disease
- First Posted Date
- 2015-09-24
- Last Posted Date
- 2021-01-08
- Lead Sponsor
- Takeda
- Target Recruit Count
- 11
- Registration Number
- NCT02559713
- Locations
- 🇺🇸
Atlantic Health System, Morristown, New Jersey, United States
🇺🇸Feinberg School of Medicine Northwestern University, Chicago, Illinois, United States
🇺🇸Baylor College of Medicine, Houston, Texas, United States
An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis
- Conditions
- Interventions
- First Posted Date
- 2015-07-14
- Last Posted Date
- 2020-01-28
- Lead Sponsor
- Takeda
- Target Recruit Count
- 771
- Registration Number
- NCT02497469
- Locations
- 🇺🇸
Chevy Chase Clinical Research, Chevy Chase, Maryland, United States
🇺🇸Texas Digestive Disease Consultants - Dallas, Dallas, Texas, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
Effect of Intravenous (IV) Vedolizumab on Mucosal Healing in Crohn's Disease
- First Posted Date
- 2015-04-23
- Last Posted Date
- 2018-09-14
- Lead Sponsor
- Takeda
- Target Recruit Count
- 101
- Registration Number
- NCT02425111
Corticosteroids With Vedolizumab in Crohn's Disease
- Conditions
- Interventions
- First Posted Date
- 2014-12-24
- Last Posted Date
- 2019-04-26
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 1
- Registration Number
- NCT02324699
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.